miRNAs as therapeutic tools and biomarkers for prostate cancer

Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets

Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855 · see citing works

MicroRNA expression profiles classify human cancers

Lü, J., Getz, G. A., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,497 · see citing works

Circulating microRNAs as stable blood-based markers for cancer detection

Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969 · see citing works

MicroRNA signatures in human cancers

Calin, G. A., & Croce, C. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1997 · Cited by 7,592 · see citing works

Oncomirs — microRNAs with a role in cancer

Esquela‐Kerscher, A., & Slack, F. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1840 · Cited by 7,038 · see citing works

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Fitzmaurice, C., Allen, C., Barber, R. M., Barregård, L., Bhutta, Z. A., Brenner, H., Dicker, D., Chimed‐Ochir, O., Dandona, R., Dandona, L., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,229 · see citing works

The Versatile Role of microRNA-30a in Human Cancer

Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409 · see citing works

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma

Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294 · see citing works

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

Fitzmaurice, C., Abate, D., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdel-Rahman, O. M., Abdelalim, A., Abdoli, A., Abdollahpour, I., Abdulle, A. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2996 · Cited by 2,521 · see citing works

MicroRNAs in cancer: biomarkers, functions and therapy

Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049 · see citing works

MicroRNA profiling: approaches and considerations

Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3198 · Cited by 1,765 · see citing works

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study.

Fitzmaurice, C. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1568 · Cited by 1,721 · see citing works

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

Fitzmaurice, C., Akinyemiju, T., Lami, F., Alam, S., Alizadeh‐Navaei, R., Allen, C., Alsharif, U., Alvis‐Guzmán, N., Amini, E., Anderson, B. O., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2706 · Cited by 1,520 · see citing works

MicroRNAs in body fluids—the mix of hormones and biomarkers

Cortez, M. A., Bueso-Ramos, C., Ferdin, J., Lopez‐Berestein, G., Sood, A. K., & Călin, G. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.76 · Cited by 1,471 · see citing works

The chemical evolution of oligonucleotide therapies of clinical utility

Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216 · see citing works

Overcoming cellular barriers for RNA therapeutics

Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139 · see citing works

MicroRNA and cancer

Jansson, M., & Lund, A. H. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.006 · Cited by 1,120 · see citing works

Quantitative and stoichiometric analysis of the microRNA content of exosomes

Chevillet, J. R., Kang, Q., Ruf, I. K., Briggs, H., Vojtech, L. N., Hughes, S. M., Cheng, H. H., Arroyo, J. D., Meredith, E. K., Gallichotte, E. N., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408301111 · Cited by 1,105 · see citing works

The majority of microRNAs detectable in serum and saliva is concentrated in exosomes

Gallo, A., Tandon, M., Alevizos, I., & Illei, G. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030679 · Cited by 1,060 · see citing works

The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D’Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1880 · Cited by 989 · see citing works

MicroRNAs: Synthesis, mechanism, function, and recent clinical trials

Wahid, F., Shehzad, A., Khan, T., & Kim, Y. Y. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.06.013 · Cited by 902 · see citing works

The delivery of therapeutic oligonucleotides

Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 863 · see citing works

Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs

Garcia, D. M., Baek, D., Shin, C., Bell, G. W., Grimson, A., & Bartel, D. P. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2115 · Cited by 859 · see citing works

Assessing sample and miRNA profile quality in serum and plasma or other biofluids

Blöndal, T., Nielsen, S. J., Baker, A., Andreasen, D., Mouritzen, P., Teilum, M. W., & Dahlsveen, I. K. (2012) · Methods · doi:10.1016/j.ymeth.2012.09.015 · Cited by 695 · see citing works

miR-15a and miR-16-1 in cancer: discovery, function and future perspectives

Aqeilan, R. I., Calin, G. A., & Croce, C. M. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.69 · Cited by 650 · see citing works

Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing

Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 590 · see citing works

Exploring miRNA based approaches in cancer diagnostics and therapeutics

Mishra, S., Yadav, T., & Rani, V. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.003 · Cited by 494 · see citing works

Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology

Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437 · see citing works

Chemical modification and design of anti-miRNA oligonucleotides

Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 432 · see citing works

Cationic lipids and polymers mediated vectors for delivery of siRNA

Zhang, S., Zhao, B., Jiang, H., Wang, B., & Ma, B. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.07.016 · Cited by 421 · see citing works

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment

Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., Dunn, R. L., Meyer, S., Hodge, P., Groskopf, J., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.039 · Cited by 394 · see citing works

The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis

Korpal, M., & Kang, Y. (2008) · RNA Biology · doi:10.4161/rna.5.3.6558 · Cited by 375 · see citing works

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score

Neste, L. V., Hendriks, R. J., Dijkstra, S., Trooskens, G., Cornel, E. B., Jannink, S. A., de Jong, H., Hessels, D., Smit, F. P., Melchers, W. J. G., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.04.012 · Cited by 374 · see citing works

Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine

Cheng, L., Sun, X., Scicluna, B. J., Coleman, B. M., & Hill, A. F. (2013) · Kidney International · doi:10.1038/ki.2013.502 · Cited by 369 · see citing works

Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability

Godbey, W. T., Wu, K. K., & Mikos, A. G. (2001) · Biomaterials · doi:10.1016/s0142-9612(00)00203-9 · Cited by 361 · see citing works

miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase Cε

Gandellini, P., Folini, M., Longoni, N., Pennati, M., Binda, M., Colecchia, M., Salvioni, R., Supino, R., Moretti, R. M., Limonta, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2894 · Cited by 358 · see citing works

MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges

Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 333 · see citing works

Treating cancer with microRNA replacement therapy: A literature review

Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26514 · Cited by 307 · see citing works

Plasma processing conditions substantially influence circulating microRNA biomarker levels

Cheng, H. H., Yi, H. S., Kim, Y., Kroh, E. M., Chien, J. W., Eaton, K. D., Goodman, M. T., Tait, J. F., Tewari, M., & Pritchard, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064795 · Cited by 283 · see citing works

How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market.

Bonneau, É., Neveu, B., Kostantin, E., Tsongalis, G. J., & Guire, V. D. (2019) · PubMed Central · Cited by 244 · see citing works

Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer

Musumeci, M., Coppola, V., Addario, A., Patrizii, M., Maugeri‐Saccà, M., Memeo, L., Colarossi, C., Francescangeli, F., Biffoni, M., Collura, D., et al. (2011) · Oncogene · doi:10.1038/onc.2011.140 · Cited by 236 · see citing works

Dysregulation of microRNA biogenesis and gene silencing in cancer

Hata, A., & Lieberman, J. (2015) · Science Signaling · doi:10.1126/scisignal.2005825 · Cited by 235 · see citing works

miR-21: an oncomir on strike in prostate cancer

Folini, M., Gandellini, P., Longoni, N., Profumo, V., Callari, M., Pennati, M., Colecchia, M., Supino, R., Veneroni, S., Salvioni, R., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-12 · Cited by 229 · see citing works

MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes

Liu, C., Liu, R., Zhang, D., Deng, Q., Liu, B., Chao, H., Rycaj, K., Takata, Y., Lin, K., Lu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14270 · Cited by 229 · see citing works

Comprehensive microRNA Profiling of Prostate Cancer

Walter, B. A., Valera, V., Pinto, P. A., & Merino, M. J. (2013) · Journal of Cancer · doi:10.7150/jca.6394 · Cited by 225 · see citing works

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer

Jalava, S. E., Urbanucci, A., Latonen, L., Waltering, K. K., Sahu, B., Jänne, O. A., Seppälä, J., Lähdesmäki, H. J., Tammela, T. L. J., & Visakorpi, T. (2012) · Oncogene · doi:10.1038/onc.2011.624 · Cited by 221 · see citing works

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA

Fleshner, K. A., Carlsson, S., & Roobol, M. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.251 · Cited by 220 · see citing works

Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM

Kong, D., Heath, E. I., Chen, W., Cher, M. L., Powell, I. J., Heilbrun, L. K., Li, Y., Ali, S. S., Sethi, S. N., Hassan, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033729 · Cited by 220 · see citing works

INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES

van de Water, F. M., Boerman, O. C., Wouterse, A. C., Peters, J. G. P., Rüssel, F. G. M., & Masereeuw, R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009555 · Cited by 217 · see citing works

MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms

Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2010) · The Prostate · doi:10.1002/pros.21185 · Cited by 205 · see citing works

Computational Methods for MicroRNA Target Prediction

Ekimler, S., & Sahin, K. (2014) · Genes · doi:10.3390/genes5030671 · Cited by 193 · see citing works

miR‐125b promotes growth of prostate cancer xenograft tumor through targeting pro‐apoptotic genes

Shi, X.-B., Xue, L., Ma, A., Tepper, C. G., Kung, H., & White, R. D. (2010) · The Prostate · doi:10.1002/pros.21270 · Cited by 191 · see citing works

MicroRNA Detection: Current Technology and Research Strategies

Hunt, E. A., Broyles, D. B., Head, T., & Daunert, S. (2015) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-071114-040343 · Cited by 191 · see citing works

Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment

Ibsen, S., Schutt, C. E., & Esener, S. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s31564 · Cited by 187 · see citing works

MicroRNA let-7c Is Downregulated in Prostate Cancer and Suppresses Prostate Cancer Growth

Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Shi, X.-B., Zou, J. X., Chen, H.-W., Zhang, J., Chen, X., Luo, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032832 · Cited by 178 · see citing works

Journey of siRNA: Clinical Developments and Targeted Delivery

Nikam, R. R., & Gore, K. R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0715 · Cited by 175 · see citing works

MiR‐146a suppresses tumor growth and progression by targeting EGFR pathway and in a p‐ERK‐dependent manner in castration‐resistant prostate cancer

Xu, B., Wang, N., Wang, X., Tong, N., Shao, N., Tao, J., Li, P., Niu, X., Feng, N., Zhang, L., et al. (2011) · The Prostate · doi:10.1002/pros.22466 · Cited by 167 · see citing works

MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer

Rokhlin, O. W., Scheinker, V., Taghiyev, A. F., Bumcrot, D. A., Glover, R. A., & Cohen, M. B. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6284 · Cited by 159 · see citing works

Interplay of microRNAs, transcription factors and target genes: linking dynamic expression changes to function

Nazarov, P. V., Reinsbach, S. E., Muller, A., Nicot, N., Philippidou, D., Vallar, L., & Kreis, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1471 · Cited by 151 · see citing works

Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling

Tang, Y., Pan, J., Huang, S., Peng, X., Zou, X., Luo, Y., Ren, D., Zhang, X., Li, R., He, P., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0813-4 · Cited by 150 · see citing works

microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor

Lu, Q. (2012) · Oncology Reports · doi:10.3892/or.2012.1711 · Cited by 148 · see citing works

Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo

Zhupanyn, P., Ewe, A., Büch, T., Malek, A. V., Rademacher, P., Müller, C., Reinert, A., Jaimes, Y., & Aigner, A. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.032 · Cited by 146 · see citing works

Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition

Porzycki, P., Ciszkowicz, E., Semik, M., & Tyrka, M. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-1938-2 · Cited by 146 · see citing works

PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study

Gittelman, M., Hertzman, B., Bailen, J. L., Williams, T., Koziol, I., Henderson, R. J., Efros, M. D., Bidair, M., & Ward, J. F. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.02.018 · Cited by 145 · see citing works

Multicenter Evaluation of [−2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer

Stephan, C., Vincendeau, S., Houlgatte, A., Cammann, H., Jung, K., & Semjonow, A. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.195784 · Cited by 139 · see citing works

miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer

Li, T., Li, R., Li, Y., Zhong, S., Chen, Y., Zhang, C.-M., Hu, M.-M., & Shen, Z. (2012) · The Journal of Urology · doi:10.1016/j.juro.2011.11.082 · Cited by 138 · see citing works

Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer

Fletcher, C. E., Dart, D. A., Sita-Lumsden, A. R., Cheng, H., Rennie, P. S., & Bevan, C. L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds139 · Cited by 138 · see citing works

MicroRNAs in cancer biology and therapy: Current status and perspectives

Price, C. O., & Chen, J. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.06.004 · Cited by 137 · see citing works

MicroRNAs in prostate cancer: Functional role as biomarkers

Kanwal, R., Plaga, A. R., Liu, X., Shukla, G. C., & Gupta, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.011 · Cited by 137 · see citing works

Micrornas in prostate cancer: an overview

Vanacore, D., Boccellino, M., Rossetti, S., Cavaliere, C., D’Aniello, C., Franco, R. D., Romano, F. J., Montanari, M., Mantia, E. L., Piscitelli, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16933 · Cited by 136 · see citing works

miRNA-128 Suppresses Prostate Cancer by Inhibiting BMI-1 to Inhibit Tumor-Initiating Cells

Jin, M., Zhang, T., Liu, C., Badeaux, M. A., Liu, B., Liu, R., Jeter, C. R., Chen, X., Vlassov, A. V., & Tang, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0404 · Cited by 135 · see citing works

Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer

Urabe, F., Matsuzaki, J., Yamamoto, Y., Kimura, T., Hara, T., Ichikawa, M., Takizawa, S., Aoki, Y., Niida, S., Sakamoto, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2849 · Cited by 127 · see citing works

miR 488* inhibits androgen receptor expression in prostate carcinoma cells

Sikand, K., Slaibi, J. E., Singh, R., Slane, S. D., & Shukla, G. C. (2010) · International Journal of Cancer · doi:10.1002/ijc.25753 · Cited by 124 · see citing works

Polymeric nanoparticles for siRNA delivery: Production and applications

Cavallaro, G., Sardo, C., Craparo, E. F., Porsio, B., & Giammona, G. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.04.008 · Cited by 118 · see citing works

The role of microRNAs in metastasis and epithelial-mesenchymal transition

Bracken, C. P., Gregory, P. A., Khew‐Goodall, Y., & Goodall, G. J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8750-1 · Cited by 117 · see citing works

Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine

Fredsøe, J., Rasmussen, A. K. I., Thomsen, A. R., Mouritzen, P., Høyer, S., Borre, M., Orntoft, T. F., & Sørensen, K. D. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.02.018 · Cited by 116 · see citing works

miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p levels in urine—promising biomarkers for the identification of prostate and bladder cancer

Ghorbanmehr, N., Gharbi, S., Korsching, E., Tavallaei, M., Einollahi, B., & Mowla, S. J. (2018) · The Prostate · doi:10.1002/pros.23714 · Cited by 116 · see citing works

MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo

Hsu, T.-I., Hsu, C.-H., Lee, K.-H., Lin, J.-T., Chen, C.-S., Chang, K.-C., Su, C., Hsiao, M., & Lu, P.-J. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.12 · Cited by 114 · see citing works

MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells

Liu, X., Chen, Q., Yan, J. Y., Wang, Y., Zhu, C., Chen, C., Zhao, X., Xu, M., Sun, Q., Deng, R., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.458 · Cited by 113 · see citing works

Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2

Kroiss, A., Vincent, S., Decaussin‐Petrucci, M., Meugnier, E., Viallet, J. P., Ruffion, A., Chalmel, F., Samarut, J., & Allioli, N. (2014) · Oncogene · doi:10.1038/onc.2014.222 · Cited by 113 · see citing works

The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression

Lo, U., Lee, C., Lee, M., & Hsieh, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102079 · Cited by 109 · see citing works

Computational Methods for MicroRNA Target Prediction

Watanabe, Y., Tomita, M., & Kanai, A. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)27004-1 · Cited by 107 · see citing works

MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer

Verdoodt, B., Neid, M., Vogt, M., KUHN, V., Liffers, S., Palisaar, R., Noldus, J., Tannapfel, A., & Mirmohammadsadegh, A. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1915 · Cited by 103 · see citing works

Exosomes in diagnosis and therapy of prostate cancer

Pan, J., Ding, M., Xu, K., Yang, C., & Mao, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18532 · Cited by 103 · see citing works

MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1

Lin, Z., Huang, Y., Zhang, Y., Han, Z., He, H., Ling, X., Fu, X., Dai, Q.-S., Cai, C., Chen, J., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28707 · Cited by 102 · see citing works

A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer

Matin, F., Jeet, V., Moya, L., Selth, L. A., Chambers, S. K., BioResource, A. P. C., Yeadon, T. M., Saunders, P. T. K., Eckert, A., Heathcote, P. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24424-w · Cited by 102 · see citing works

Exosome-like Nanovectors for Drug Delivery in Cancer

Arrighetti, N., Corbo, C., Evangelopoulos, M., Pastò, A., Zuco, V., & Tasciotti, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180831150259 · Cited by 102 · see citing works

Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction

Bidarra, D., Constâncio, V., Barros‐Silva, D., Ramalho-Carvalho, J., Moreira-Barbosa, C., Antunes, L., Maurício, J., Oliveira, J., Henrique, R., & Jerónimo, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00900 · Cited by 101 · see citing works

The altered expression of MiR‐221/‐222 and MiR‐23b/‐27b is associated with the development of human castration resistant prostate cancer

Sun, T., Yang, M., Chen, S., Balk, S. P., Pomerantz, M. M., Hsieh, C.-L., Brown, M. A., Lee, G. M., & Kantoff, P. W. (2011) · The Prostate · doi:10.1002/pros.22456 · Cited by 100 · see citing works

miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study

Yu, Y., Guo, J., & Shao, Z. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.09.011 · Cited by 99 · see citing works

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients

Avgeris, M., STRAVODIMOS, K. G., Fragoulis, E. G., & Scorilas, A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.250 · Cited by 98 · see citing works

miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis

Bezawy, R. E., Cominetti, D., Fenderico, N., Zuco, V., Beretta, G. L., Dugo, M., Arrighetti, N., Stucchi, C., Rancati, T., Valdagni, R., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.033 · Cited by 97 · see citing works

miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells

Pennati, M., Lopergolo, A., Profumo, V., Cesare, M. D., Sbarra, S., Valdagni, R., Zaffaroni, N., Gandellini, P., & Folini, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.009 · Cited by 93 · see citing works

Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells

Lin, Y., Lin, J., Tsai, T., Chou, K., Chen, H., & Hwang, T. I. (2016) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2016.07.001 · Cited by 92 · see citing works

Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs

Nguyen, D.-D., & Chang, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010065 · Cited by 90 · see citing works

Oncomir miR-125b Suppresses p14ARF to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer

Amir, S., Ma, A., Shi, X.-B., Xue, L., Kung, H.-J., & White, R. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061064 · Cited by 90 · see citing works

A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening

Vickers, A. J., Gupta, A., Savage, C. J., Pettersson, K. S. I., Dahlin, A., Bjartell, A. S., Manjer, J., Scardino, P. T., Ulmert, D., & Lilja, H. G. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1003 · Cited by 90 · see citing works

Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer

Yang, Y., Jia, D., Kim, H., Elmageed, Z. Y. A., Datta, A., Davis, R., Srivastav, S., Moroz, K., Crawford, B. E., Moparty, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1606 · Cited by 89 · see citing works

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression

Dallavalle, C., Albino, D., Civenni, G., Merulla, J., Ostano, P., Grand, M. M., Rossi, S., Losa, M., D’Ambrosio, G., Sessa, F., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86505 · Cited by 88 · see citing works

Overexpression of miR-145–5p Inhibits Proliferation of Prostate Cancer Cells and Reduces SOX2 Expression

Özen, M., Karataş, Ö. F., Güllüoğlu, Ş., Karataş, Ö. F., Sevli, S., Güzel, E., Ekici, I. D., Çaşkurlu, T., Solak, M., Creighton, C. J., et al. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1025407 · Cited by 88 · see citing works

Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis

Moya, L., Meijer, J., Schubert, S., Matin, F., & Batra, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051154 · Cited by 88 · see citing works

miR-205 regulates basement membrane deposition in human prostate: implications for cancer development

Gandellini, P., Profumo, V., Casamichele, A., Fenderico, N., Borrelli, S., Petrovich, G., Santilli, G., Callari, M., Colecchia, M., Pozzi, S., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.56 · Cited by 87 · see citing works

miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1

Yu, J., Lu, Y., Cui, D., Li, E., Zhu, Y., Zhao, Y., Zhao, F., & Xia, S. (2013) · Oncology Reports · doi:10.3892/or.2013.2897 · Cited by 85 · see citing works

The Use of Biomarkers in Prostate Cancer Screening and Treatment.

Alford, A. V., Brito, J. M., Yadav, K. K., Yadav, S. S., Tewari, A. K., & Renzulli, J. (2017) · PubMed Central · doi:10.3909/riu0772 · Cited by 79 · see citing works

Aberrant microRNA Expression Likely Controls RAS Oncogene Activation During Malignant Transformation of Human Prostate Epithelial and Stem Cells by Arsenic

Ngalame, N. N. O., Tokar, E. J., Person, R. J., Xu, Y., & Waalkes, M. P. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu002 · Cited by 78 · see citing works

Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer

Wan, Y., Zeng, Z.-C., Xi, M., Song, W., Hua, W., Liu, Y., Zhou, Y., Luo, H., Jiang, F., & Zhong, W. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.10.027 · Cited by 77 · see citing works

An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions

Zhang, H.-L., Qin, X.-J., Cao, D., Zhu, Y., Yao, X.-D., Zhang, S.-L., Dai, B., & Ye, D. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2012.116 · Cited by 76 · see citing works

miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition

Bezawy, R. E., Tinelli, S., Tortoreto, M., Doldi, V., Zuco, V., Folini, M., Stucchi, C., Rancati, T., Valdagni, R., Gandellini, P., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1060-z · Cited by 75 · see citing works

Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo

Ewe, A., Panchal, O., Pinnapireddy, S. R., Bakowsky, U., Przybylski, S., Temme, A., & Aigner, A. M. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.08.005 · Cited by 74 · see citing works

Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer

Nip, H., Dar, A. A., Saini, S., Colden, M., Shahryari, V., Chowdhary, H., Yamamura, S., Mitsui, Y., Tanaka, Y., Kato, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12031 · Cited by 73 · see citing works

Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model

Banyard, J., Chung, I., Wilson, A. M., Vetter, G., Béchec, A. L., Bielenberg, D. R., & Zetter, B. R. (2013) · Scientific Reports · doi:10.1038/srep03151 · Cited by 71 · see citing works

miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells

Zhu, C. Y., Li, J., Cheng, G., Zhou, H., Tao, L., Cai, H., Li, P., Cao, Q., Ju, X., Meng, X., et al. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1628-4 · Cited by 69 · see citing works

miR-10a-5p and miR-29b-3p as Extracellular Vesicle-Associated Prostate Cancer Detection Markers

Worst, T. S., Previti, C., Nitschke, K., Diessl, N., Gross, J. C., Hoffmann, L., Frey, L. M., Thomas, V., Kahlert, C., Bieback, K., et al. (2019) · Cancers · doi:10.3390/cancers12010043 · Cited by 69 · see citing works

Polyethylenimine-based Formulations for Delivery of Oligonucleotides

Hao, F., Li, Y., Zhu, J., Sun, J., Marshall, B., Lee, R. J., Teng, L., Yang, Z., & Xie, J. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181031094759 · Cited by 69 · see citing works

Regulation of miR-200c and miR-141 by Methylation in Prostate Cancer

Lynch, S. M., O’Neill, K. M., McKenna, M. M., Walsh, C. P., & McKenna, D. J. (2016) · The Prostate · doi:10.1002/pros.23201 · Cited by 68 · see citing works

Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer

LI, W., Dong, Y., Wang, K., DENG, Z., Zhang, W., & SHEN, H. F. (2020) · Neoplasma · doi:10.4149/neo_2020_191130n1234 · Cited by 67 · see citing works

MicroRNAs in prostate cancer

Kim, W. T., & Kim, W.-J. (2013) · Prostate International · doi:10.12954/pi.12011 · Cited by 66 · see citing works

The Prostate Health Index

Lepor, A., Catàlona, W. J., & Loeb, S. (2015) · Urologic Clinics of North America · doi:10.1016/j.ucl.2015.08.001 · Cited by 66 · see citing works

Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression

Wan, X., Huang, W., Yang, S., Zhang, Y., Zhang, P., Kong, Z., Li, T., Wu, H., Jing, F., & Li, Y. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.08.043 · Cited by 64 · see citing works

Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

Siu, M. K., Abou-Kheir, W. G., Yin, J. J., Chang, Y.-S., Barrett, B., Suau, F., Casey, O. M., Chen, W., Fang, L., Hynes, P. G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1994 · Cited by 62 · see citing works

miR-154 inhibits prostate cancer cell proliferation by targeting CCND2

Zhu, C. Y., Shao, P., Bao, M., Li, P., Zhou, H., Cai, H., Cao, Q., Tao, L., Meng, X., Ju, X., et al. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.11.013 · Cited by 62 · see citing works

The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer

Ottman, R., Levy, J., Grizzle, W. E., & Chakrabarti, R. (2016) · Oncotarget · doi:10.18632/oncotarget.12061 · Cited by 62 · see citing works

miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis

Seashols‐Williams, S. J., Budd, W. T., Clark, G. C., Wu, Q., Daniel, R., Dragoescu, E. A., & Zehner, Z. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159601 · Cited by 61 · see citing works

miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression

Chakravarthi, B. V. S. K., Chandrashekar, D. S., Agarwal, S., Balasubramanya, S. A. H., Pathi, S. S., Goswami, M. T., Jing, X., Wang, R., Mehra, R., Asangani, I. A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0230 · Cited by 59 · see citing works

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment

Ferroni, C., Pepe, A., Kim, Y. S., Lee, S., Guerrini, A., Parenti, M. D., Tesei, A., Zamagni, A., Cortesi, M., Zaffaroni, N., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00105 · Cited by 58 · see citing works

MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients’ Samples

Cannistraci, A., Pace, A. L. D., Maria, R. D., & Bonci, D. (2014) · BioMed Research International · doi:10.1155/2014/146170 · Cited by 56 · see citing works

MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis

Liu, X., Luo, X., Wu, Y., Xia, D., Chen, W., Fang, Z., Deng, J., Hao, Y., Yang, X., Zhang, T., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494004 · Cited by 56 · see citing works

Decreased miR-218–5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer

Peng, P., Chen, T., Wang, Q., Zhang, Y., Zheng, F., Huang, S., Tang, Y., Yang, C., Ding, W., Ren, D., et al. (2019) · Oncology Research and Treatment · doi:10.1159/000495473 · Cited by 56 · see citing works

Polymers for Nucleic Acid Transfer—An Overview

Wagner, E. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00008-0 · Cited by 55 · see citing works

Cationic Polymer Nanoparticles-Mediated Delivery of miR-124 Impairs Tumorigenicity of Prostate Cancer Cells

Conte, R., Valentino, A., Cristo, F. D., Peluso, G., Cerruti, P., Salle, A. D., & Calarco, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030869 · Cited by 54 · see citing works

miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy

Nagesh, P. K. B., Chowdhury, P., Hatami, E., Boya, V. K. N., Kashyap, V. K., Khan, S., Hafeez, B. B., Chauhan, S. C., Jaggi, M., & Yallapu, M. M. (2018) · Cancers · doi:10.3390/cancers10090289 · Cited by 52 · see citing works

miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases

Amankwah, E. K., Anegbe, E., Park, H., Pow‐Sang, J. M., Hakam, A., & Park, J. Y. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2012.160 · Cited by 52 · see citing works

Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX

Rea, D., Vecchio, V. D., Palma, G., Barbieri, A., Falco, M., Luciano, A., Biase, D. D., Perdonà, S., Facchini, G., & Arra, C. (2016) · BioMed Research International · doi:10.1155/2016/9750795 · Cited by 51 · see citing works

Technical Factors Involved in the Measurement of Circulating MicroRNA Biomarkers for the Detection of Colorectal Neoplasia

Yamada, A., Cox, M. A., Gaffney, K., Moreland, A., Boland, C. R., & Goel, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112481 · Cited by 51 · see citing works

MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics

Gordanpour, A., Nam, R. K., Sugar, L., & Seth, A. K. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.3 · Cited by 51 · see citing works

LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation

Profumo, V., Forte, B., Percio, S., Rotundo, F., Doldi, V., Ferrari, E., Fenderico, N., Dugo, M., Romagnoli, D., Benelli, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08153-2 · Cited by 51 · see citing works

MicroRNA-335 and -543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase

Fu, Q., LIU, X., LIU, Y., YANG, J., Lv, G., & Dong, S.-F. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2355 · Cited by 50 · see citing works

Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis

Liu, Y., Yin, J., Barrett, B., Sheppard, H., Li, D., Casey, O. M., Fang, L., Hynes, P. G., Ameri, A. H., & Kelly, K. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00008-15 · Cited by 50 · see citing works

Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression

Zuo, Z., Yu, Y. P., Ding, Y., Liu, S., Martin, A., Tseng, G. C., & Luo, J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.03.015 · Cited by 48 · see citing works

Customized Internal Reference Controls for Improved Assessment of Circulating MicroRNAs in Disease

Schlosser, K., McIntyre, L., White, R. J., & Stewart, D. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127443 · Cited by 48 · see citing works

MicroRNA-382 inhibits prostate cancer cell proliferation and metastasis through targeting COUP-TFII

Zhang, W., Liu, J., Qiu, J., Fu, X., Tang, Q., Yang, F., Zhao, Z., & Wang, H. (2016) · Oncology Reports · doi:10.3892/or.2016.5141 · Cited by 47 · see citing works

microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer

Zedan, A. H., Hansen, T. F., Assenholt, J., Plečkaitis, M., Madsen, J. S., & Osther, P. J. S. (2018) · Tumor Biology · doi:10.1177/1010428318775864 · Cited by 47 · see citing works

Functional roles and potential clinical application of miRNA‐345‐5p in prostate cancer

Tınay, İ., Tan, M., Gui, B., Werner, L. L., Kibel, A. S., & Li, J. (2018) · The Prostate · doi:10.1002/pros.23650 · Cited by 45 · see citing works

Redox-Sensitive PEG–Polypeptide Nanoporous Particles for Survivin Silencing in Prostate Cancer Cells

Cavalieri, F., Beretta, G. L., Cui, J., Braunger, J. A., Yan, Y., Richardson, J. J., Tinelli, S., Folini, M., Zaffaroni, N., & Caruso, F. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00562 · Cited by 43 · see citing works

Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population

Lyu, J., Lin, Z., Wang, F., Ji, J., Cao, Z., Xu, H., Shi, X., Zhu, Y., Zhang, C., Guo, F., et al. (2019) · BioMed Research International · doi:10.1155/2019/9306803 · Cited by 40 · see citing works

Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention

Guo, X., Han, T., Hu, P., Guo, X., Zhu, C., Wang, Y., & Chang, S. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-2009-4 · Cited by 39 · see citing works

Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy

Zedan, A. H., Hansen, T. F., Assenholt, J., Madsen, J. S., & Osther, P. J. S. (2018) · The Prostate · doi:10.1002/pros.23748 · Cited by 38 · see citing works

Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer

Păunescu, I. A., Bardan, R. T., Marcu, A., Nițușcă, D., Dema, A. L. C., Negru, S. M., Bălăcescu, O., Bălăcescu, L., Cumpănaş, A. A., Sîrbu, I. O., et al. (2019) · Medicina · doi:10.3390/medicina55090564 · Cited by 38 · see citing works

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study

Benoist, G. E., van Oort, I. M., Boerrigter, E., Verhaegh, G. W. C. T., van Hooij, O., Groen, L., Smit, F. P., de Mol, P., Hamberg, P., Dezentjé, V. O., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa095 · Cited by 38 · see citing works

Diagnostic and prognostic value of serum miR‐15a and miR‐16‐1 expression among egyptian patients with prostate cancer

Zidan, H. E., Abdul‐Maksoud, R. S., Elsayed, W. S. H., & Desoky, E. A. M. (2018) · IUBMB Life · doi:10.1002/iub.1733 · Cited by 37 · see citing works

Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance

Liu, R. S. C., Olkhov‐Mitsel, E., Jeyapala, R., Zhao, F., Commisso, K., Klotz, L. H., Loblaw, A., Liu, S. K., Vesprini, D., Fleshner, N. E., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.12.006 · Cited by 36 · see citing works

Emerging role of microRNAs in prostate cancer: implications for personalized medicine.

Gandellini, P., Folini, M., & Zaffaroni, N. (2010) · PubMed · Cited by 36 · see citing works

Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy

Beretta, G. L., & Cavalieri, F. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666151006094559 · Cited by 36 · see citing works

The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms

Konoshenko, M. Y., Lekchnov, E. A., Bryzgunova, O. E., Zaporozhchenko, I. A., Yarmoschuk, S. V., Pashkovskaya, O. A., Pak, S. V., & Laktionov, P. P. (2020) · Diagnostics · doi:10.3390/diagnostics10010038 · Cited by 35 · see citing works

microRNA-372 Suppresses Migration and Invasion by Targeting p65 in Human Prostate Cancer Cells

Kong, X., Qian, X., Duan, L., Liu, H., Zhu, Y., & Qi, J. (2016) · DNA and Cell Biology · doi:10.1089/dna.2015.3186 · Cited by 35 · see citing works

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone‐sensitive prostate cancer

Cheng, H. H., Plets, M., Li, H., Higano, C. S., Tangen, C. M., Agarwal, N., Vogelzang, N. J., Hussain, M., Thompson, I. M., Tewari, M., et al. (2017) · The Prostate · doi:10.1002/pros.23452 · Cited by 35 · see citing works

Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection

Grand, M. M., Gregnanin, I., Sacchetto, L., Ostano, P., Zitella, A., Bottoni, G., Oderda, M., Marra, G., Munegato, S., Pardini, B., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy167 · Cited by 34 · see citing works

Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia

Jin, W., Fei, X., Wang, X., Chen, F., & Song, Y. (2020) · Journal of Immunology Research · doi:10.1155/2020/5873056 · Cited by 34 · see citing works

MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity

Wang, Y., Shao, N., Mao, X., Zhu, M., Fan, W., Shen, Z., Xiao, R., Wang, C., Wenping, B., Xu, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10165 · Cited by 33 · see citing works

Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification

Al‐Kafaji, G., Said, H. M., Alam, M., & Naieb, Z. A. (2018) · Oncology Letters · doi:10.3892/ol.2018.8778 · Cited by 33 · see citing works

MicroRNAs as prognostic markers in prostate cancer

Süer, İ., Güzel, E., Karataş, Ö. F., Creighton, C. J., Ittmann, M., & Özen, M. (2018) · The Prostate · doi:10.1002/pros.23731 · Cited by 33 · see citing works

Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance

Zhao, F., Vesprini, D., Liu, R. S. C., Olkhov‐Mitsel, E., Klotz, L. H., Loblaw, A., Liu, S. K., & Bapat, B. V. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.01.031 · Cited by 32 · see citing works

The role of microRNAs in prostate cancer progression.

Lo, U., Yang, D., & Hsieh, J. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.08.01 · Cited by 31 · see citing works

Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential

Fredsøe, J., Rasmussen, A. K. I., Mouritzen, P., Bjerre, M. T., Østergren, P. B., Fode, M. M., Borre, M., & Sørensen, K. D. (2020) · Diagnostics · doi:10.3390/diagnostics10040188 · Cited by 31 · see citing works

Exploring the Potential of MicroRNA Let-7c as a Therapeutic for Prostate Cancer

Mulholland, E. J., Green, W. P., Buckley, N. E., & McCarthy, H. O. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.09.031 · Cited by 30 · see citing works

Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer

Torbati, P. M., Asadi, F., & Fard‐Esfahani, P. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.5.1453 · Cited by 30 · see citing works

A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer

Farran, B., Dyson, G. E., Craig, D., Dombkowski, A. A., Beebe‐Dimmer, J., Powell, I. J., Podgorski, I., Heilbrun, L. K., Bolton, S., & Bock, C. H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy025 · Cited by 28 · see citing works

Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer

Mao, Z., Ji, A., Yang, K., He, W., Hu, Y., Zhang, Q., Zhang, D., & Xie, L. (2018) · Medicine · doi:10.1097/md.0000000000012806 · Cited by 28 · see citing works

Diagnostic significance of miR‐21, miR‐141, miR‐18a and miR‐221 as novel biomarkers in prostate cancer among Egyptian patients

Ibrahim, N. H., Abdellateif, M. S., Kassem, S., Salam, M. A. A. E., & Gammal, M. M. E. (2019) · Andrologia · doi:10.1111/and.13384 · Cited by 27 · see citing works

miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas

Tseng, J. H., Bisogna, M., Hoang, L. N., Olvera, N., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., Sood, A. K., Levine, D. A., & Jelinic, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-03972-7 · Cited by 27 · see citing works

miR-301a expression: Diagnostic and prognostic marker for prostate cancer

Kolluru, V., Chandrasekaran, B., Tyagi, A., Dervishi, A., Ankem, M. K., Yan, X., Kong, M., Alatassi, H., Shaheen, S. P., Messer, J. C., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.07.014 · Cited by 27 · see citing works

The role of tissue microarray in the era of target-based agents

Franco, R., Caraglia, M., Facchini, G., Abbruzzese, A., & Botti, G. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.65 · Cited by 26 · see citing works

Oncology Nurses' Use of National Comprehensive Cancer Network Clinical Practice Guidelines for Chemotherapy-Induced and Febrile Neutropenia

Nirenberg, A., Reame, N. K., Cato, K., & Larson, E. (2010) · Oncology nursing forum · doi:10.1188/10.onf.765-773 · Cited by 26 · see citing works

Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo

Wach, S., Brandl, M., Borchardt, H., Weigelt, K., Lukat, S., Nolte, E., Al-Janabi, O., Hart, M., Grässer, F. A., Giedl, J., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.020 · Cited by 26 · see citing works

MiR-34a affects G2 arrest in prostate cancer PC3 cells via Wnt pathway and inhibits cell growth and migration.

Dong, B., Gc, X., St, L., Liu, T., & Geng, B. (2020) · PubMed · doi:10.26355/eurrev_202008_22631 · Cited by 26 · see citing works

Programing Assembling/Releasing Multifunctional miRNA Nanomedicine to Treat Prostate Cancer

Ma, D., Liu, H., Zhao, P., Li, Y., Zou, H., Zhao, X., Dai, H., Kong, X., & Liu, P. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b21707 · Cited by 25 · see citing works

MicroRNA-30a functions as tumor suppressor and inhibits the proliferation and invasion of prostate cancer cells by down-regulation of SIX1

Zhu, Q., Li, H., Li, Y., & Jiang, L. (2017) · Human Cell · doi:10.1007/s13577-017-0170-1 · Cited by 24 · see citing works

Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer

Borkowetz, A., Lohse-Fischer, A., Scholze, J., Lotzkat, U., Thomas, C., Wirth, M. P., Fuessel, S., & Erdmann, K. (2020) · Diagnostics · doi:10.3390/diagnostics10080578 · Cited by 24 · see citing works

Novel Prostate Cancer Biomarkers Derived from Autoantibody Signatures

Schipper, M. J., Wang, G., Giles, N., & Ohrnberger, J. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.02.003 · Cited by 21 · see citing works

Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer

Beretta, G. L., & Zaffaroni, N. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00369 · Cited by 20 · see citing works

Ultrasound‑targeted microbubble destruction‑mediated miR‑205 enhances cisplatin cytotoxicity in prostate cancer cells

Qin, D., Li, H., & Xie, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9316 · Cited by 18 · see citing works

Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value

Cai, B., & Peng, J. (2019) · Clinical Laboratory · doi:10.7754/clin.lab.2019.190422 · Cited by 18 · see citing works

Codelivery of miR-4638–5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer

Jiang, W., Gao, Y., Wang, Z., Gong, C., Hu, C., Ding, X., Qiang, L., Gao, S., & Ren, F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01074 · Cited by 17 · see citing works

Role of a novel race-related tumor suppressor microRNA located in frequently deleted chromosomal locus 8p21 in prostate cancer progression

Bhagirath, D., Yang, T. L., Tabatabai, Z. L., Shahryari, V., Majid, S., Dahiya, R., Tanaka, Y., & Saini, S. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz058 · Cited by 17 · see citing works

PSMA-Targeting Reduction-Cleavable Hyperbranched Polyamide-Amine Gene Delivery System to Treat the Bone Metastases of Prostate Cancer

Ye, Y., Zhang, L., Dai, Y., Wang, Z., Li, C., Peng, Y., Ma, D., & He, P. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s268398 · Cited by 16 · see citing works

miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression

Rotundo, F., Cominetti, D., Bezawy, R. E., Percio, S., Doldi, V., Tortoreto, M., Zuco, V., Valdagni, R., Zaffaroni, N., & Gandellini, P. (2020) · Cells · doi:10.3390/cells9020435 · Cited by 15 · see citing works

Aberrant expression of miR-141 and nuclear receptor small heterodimer partner in clinical samples of prostate cancer

Khorasani, M., Teimoori‐Toolabi, L., Farivar, T. N., Asgari, M., Abolhasani, M., Shahrokh, H., Afgar, A., Kalantari, E., Peymani, A., & Mahdian, R. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170696 · Cited by 13 · see citing works

How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study

Dordoni, P., Badenchini, F., Alvisi, M. F., Menichetti, J., Luca, L. D., Florio, T. D., Magnani, T., Marenghi, C., Rancati, T., Valdagni, R., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05524-8 · Cited by 12 · see citing works

Unravelling “off-target” effects of redox-active polymers and polymer multilayered capsules in prostate cancer cells

Beretta, G. L., Folini, M., Cavalieri, F., Yan, Y., Fresch, E., Kaliappan, S., Hasenöhrl, C., Richardson, J. J., Tinelli, S., Fery, A., et al. (2015) · Nanoscale · doi:10.1039/c4nr07240e · Cited by 11 · see citing works

Diagnostic Value of Circulating miR-324 for Prostate Cancer

Jin, Y., Tong, S.-Q., & Tong, M. (2019) · Clinical Laboratory · doi:10.7754/clin.lab.2018.180932 · Cited by 10 · see citing works

Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer

Pang, C., Song, X., Fu, C., Zhang, Y., Zhang, Y., & Liu, M. (2020) · Clinical Laboratory · doi:10.7754/clin.lab.2019.190620 · Cited by 6 · see citing works

Editorial Comment to Functional significance of aberrantly expressed microRNAs in prostate cancer

Sakamoto, S. (2015) · International Journal of Urology · doi:10.1111/iju.12728 · Cited by 4 · see citing works

A review of the biological role of miRNAs in prostate cancer suppression and progression

Doghish, A. S., Ismail, A., El‐Mahdy, H. A., Elkady, M. A., Elrebehy, M. A., & Sallam, A.-A. M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.12.141 · Cited by 106 · see citing works

miRNAs as potential game-changers in bone diseases: Future medicinal and clinical uses

Doghish, A. S., Elballal, M. S., Elazazy, O. E., Elesawy, A. E., Shahin, R. K., Midan, H. M., Sallam, A.-A. M., Elbadry, A. M. M., Mohamed, A. K. I., Ishak, N. W., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154440 · Cited by 60 · see citing works

MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer

Ghamlouche, F., Yehya, A., Zeid, Y., Fakhereddine, H., Fawaz, J., Liu, Y., Al‐Sayegh, M., & Abou-Kheir, W. G. (2023) · Translational Oncology · doi:10.1016/j.tranon.2022.101613 · Cited by 56 · see citing works

Plasma-Derived Exosome MiR-19b Acts as a Diagnostic Marker for Pancreatic Cancer

Wang, L., Wu, J., Ye, N., Li, F., Zhan, H., Chen, S., & Xu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739111 · Cited by 43 · see citing works

Expression Profile of miRs in Mesial Temporal Lobe Epilepsy: Systematic Review

Yakovleva, K. D., Дмитренко, Д. В., Panina, I. S., Александровна, У. А., Александрович, Г. К., Konovalenko, O. V., Kantimirova, E. A., Novitsky, M. A., Nasyrova, R. F., & Shnayder, N. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020951 · Cited by 31 · see citing works

Epi‐miRNAs : Modern mediators of methylation status in human cancers

Papadimitriou, M., Panoutsopoulou, K., Pilala, K., Scorilas, A., & Avgeris, M. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1735 · Cited by 28 · see citing works

Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer

Gao, K., Li, X., Ni, J., Wu, B., Guo, J., Zhang, R., & Wu, G. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216247 · Cited by 28 · see citing works

Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer

Mao, Y., Yang, G., Li, Y., Liang, G., Xu, W., & Hu, M. (2022) · Cancers · doi:10.3390/cancers14153744 · Cited by 20 · see citing works

MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer

Doldi, V., Bezawy, R. E., & Zaffaroni, N. (2021) · Cancers · doi:10.3390/cancers13102380 · Cited by 18 · see citing works

Microfluidic-based prostate cancer model for investigating the secretion of prostate-specific antigen and microRNAs in vitro

Padmyastuti, A., Sarmiento, M. G., Dib, M., Ehrhardt, J., Schoon, J., Somova, M., Burchardt, M., Roennau, C., & Pinto, P. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-38834-y · Cited by 17 · see citing works

Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics

Das, S., Ganguly, S. C., Bera, S., & Kundu, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-02763-1 · Cited by 15 · see citing works

Cholesterol-Based Nanovesicles Enhance the In Vitro Cytotoxicity, Ex Vivo Intestinal Absorption, and In Vivo Bioavailability of Flutamide

Ali, M. A., Mohamed, M. I., Megahed, M. A., Abdelghany, T. M., & El‐Say, K. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111741 · Cited by 15 · see citing works

The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer

de Nóbrega, M., dos Reis, M. B., Pereira, É. R., de Souza, M. F., & Cólus, I. M. D. S. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04213-9 · Cited by 15 · see citing works

TriFusion enables accurate prediction of miRNA-disease association by a tri-channel fusion neural network

Long, S., Tang, X., Si, X., Kong, T., Zhu, Y., Wang, C., Qi, C., Mu, Z., & Liu, J. (2024) · Communications Biology · doi:10.1038/s42003-024-06734-0 · Cited by 14 · see citing works

Recent progress in microRNA research for prostate cancer

Yuan, F., Hu, Y., Lei, Y., & Jin, L. (2024) · Discover Oncology · doi:10.1007/s12672-024-01376-4 · Cited by 13 · see citing works

The miR-145–MMP1 axis is a critical regulator for imiquimod-induced cancer stemness and chemoresistance

Zhu, S., Yang, N., Niu, C., Wang, W., Wang, X., Bai, J., Qiao, Y., Deng, S., Guan, Y., & Chen, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106196 · Cited by 13 · see citing works

Microphysiological systems as models for immunologically ‘cold’ tumors

Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 12 · see citing works

Up-Regulation of LINC00665 Facilitates the Malignant Progression of Prostate Cancer by Epigenetically Silencing KLF2 Through EZH2 and LSD1

Xue, P., Yan, M., Wang, K., Gu, J., Zhong, B., & Tu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639060 · Cited by 12 · see citing works

Sulforaphane inhibits the growth of prostate cancer by regulating the microRNA-3919/DJ-1 axis

Zhang, F., Wan, X., Zhan, J., Shen, M., & Li, R. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1361152 · Cited by 10 · see citing works

CAF-derived exosomal miR-196b-5p after androgen deprivation therapy promotes epithelial-mesenchymal transition in prostate cancer cells through HOXC8/NF-κB signaling pathway

Song, X., Li, T., Zhou, W., Feng, C., Zhou, Z., Chen, Y., Deng, L., Chen, L., Zhao, J., Zhang, Y., et al. (2025) · Biology Direct · doi:10.1186/s13062-025-00667-2 · Cited by 9 · see citing works

Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders

Lui, A., Do, T., Alzayat, O., Yu, N., Phyu, S. M., Santuya, H. J., Liang, B., Kailash, V., Liu, D., Inslicht, S. S., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17040426 · Cited by 9 · see citing works

TP53 gene implications in prostate cancer evolution: potential role in tumor classification

Schițcu, V. H., Ráduly, L., Zănoagă, O., Jurj, A. M., Munteanu, V. C., Budişan, L., Petruţ, B., Braicu, C., Coman, I., & Berindan‐Neagoe, I. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2639 · Cited by 8 · see citing works

Trillin inhibits MAP3K11/NF-κB/COX-2 signaling pathways through upregulation of miR-145-5p in castration-resistant prostate cancer

Wang, Y., Peng, Y., Hao, W., He, C., Gao, X., Liang, P., Zhao, H., Wang, Y., Wang, L., Yu, Z., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111505 · Cited by 7 · see citing works

Peroxidase-mimicking Prussian blue nanoparticles versus HRP for high colorimetric detection of miRNA-141 in competitive RNA–RNA systems

Aamri, M. E., Mohammadi, H., & Amine, A. (2024) · Sensors & Diagnostics · doi:10.1039/d4sd00187g · Cited by 6 · see citing works

Inhibition of miR-20a by pterostilbene facilitates prostate cancer cells killed by NK cells via up-regulation of NKG2D ligands and TGF-β1down-regulation

Youlin, K., Simin, L., Jian, K., & Li, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14957 · Cited by 3 · see citing works

Deregulated miRNAs in enzalutamide resistant prostate cancer: A comprehensive review of key molecular alterations and clinical outcomes

Tavares, I., Morais, M., Dias, F., Medeiros, R., & Teixeira, A. L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189067 · Cited by 3 · see citing works

Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer

Skingen, V. E., Salberg, U. B., Hompland, T., Fjeldbo, C. S., Helgeland, H., Frikstad, K.-A. M., Ragnum, H. B., Vlatkovic, L., Hole, K. H., Seierstad, T., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6344 · Cited by 3 · see citing works

Circulating microRNA expression profiles to identify a potential link between prostate cancer and obesity

Arısan, S., Ozfiliz-Kilbas, P., Rencüzoğulları, Ö., Palavan-Ünsal, N., Gürkan, A. Ç., Yerlikaya, P. O., Onganer, P. U., & Arısan, E. D. (2022) · Human Gene · doi:10.1016/j.humgen.2022.201109 · Cited by 2 · see citing works

miRNA Signatures as Predictors of Therapy Response in Castration-Resistant Prostate Cancer: Insights from Clinical Liquid Biopsies and 3D Culture Models

Puente-Rivera, J., Núñez-Olvera, S. I., Fernández-Sánchez, V., Cureño-Díaz, M. A., Gómez-Zamora, E., Plascencia-Nieto, E. S., Figueroa-Angulo, E. E., & Álvarez-Sánchez, M. E. (2025) · Genes · doi:10.3390/genes16020180 · Cited by 1 · see citing works

Mechanistic role of miR-375 in regulating PDPK1 to promote progression of small bowel neuroendocrine tumors: a silico analysis

Ren, T., Zhou, L., Li, Z., Pan, M., & Han, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02872-x · Cited by 1 · see citing works

Regulatory roles of microRNAs in signaling pathways and their biomarker potential in prostate cancer

Kalarestaghi, H., Amani, N., & Shoorei, H. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04236-z · Cited by 1 · see citing works

Les marqueurs biologiques du cancer de la prostate : limites du PSA et place des nouveaux marqueurs

Hinault, C., Ghazal, K., Georges, A. D. J., Hamdi, S. M., & Gauchez, A. (2023) · Médecine Nucléaire · doi:10.1016/j.mednuc.2023.07.001 · Cited by 1 · see citing works

Effect of taxanes on the miR-106 and miR-200c expression in prostate cancer cells in vivo and in vitro

Плевако, Д. С., Knyazeva, M. S., Sidina, E., Беркут, М. В., Рева, С. А., Tolmachev, S. S., Artemyeva, A. S., Носов, А. К., & Malek, A. V. (2022) · Urology Herald · doi:10.21886/2308-6424-2022-10-4-98-108 · Cited by 1 · see citing works

Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate CancerPreprint

Wang, Y., Peng, Y., Hao, W., Gao, X., Liang, P., Zhao, H., Wang, Y., Wang, L., Yu, Z., & Liu, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3950771/v1

Diagnostic, Prognostic and Theranostic Potential of miRNAs in Prostate Cancer

Savic-Radojevic, A. R., & Pljesa-Ercegovac, M. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-51712-9_7

Trillin Inhibit NF-κB/COX-2/MAPK Signaling Pathways Through Upregulation of miR-145-5p in Castration-Resistant Prostate CancerPreprint

Wang, Y., Peng, Y., Hao, W., Gao, X., Liang, P., Zhao, H., Wang, Y., Wang, L., Yu, Z., & Liu, Z. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4795162

Tumor-on-a-Chip: From Biomimetic Tumor-Immune Microenvironments to Therapeutic Insights

Çetin, Y. (2025) · Biochemistry · doi:10.5772/intechopen.1012047

The promise of liquid biopsies in prostate cancer: a potential point-of-care modality for precision oncology

Asawa, G., Basu, B., & Basu, S. K. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2573464

Deciphering the molecular tapestry: extracellular vesicles as pioneering biomarker reservoirs for precision therapy in urogenital cancers

Elghazali, K., Ennaji, Y., Sakhi, Z., Tiabi, I., & Ennaji, M. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30225-1.00012-9

MicroRNAs: advances in biomarkers, diagnostics, and therapeutic strategies in prostate cancer

Mharrach, I., Tadlaoui, K. A., Aqerrout, M., Ouariaghli, I., & Ennaji, M. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30225-1.00049-x

Electrochemical Biosensor for Prostate Cancer

Kumar, R., Sirbaiya, A. K., Srivastava, S., & Bhat, G. (2026) · Springer eBooks · doi:10.1007/978-981-95-8644-8_4

CRISPR decodes the RNA regulatory network in prostate cancer: A review from mechanisms to precision therapeutics

Zhu, S., Gao, N., Zhang, P., Yang, Y., He, H., Jiang, J., & Li, Z. (2026) · Non-coding RNA Research · doi:10.1016/j.ncrna.2026.05.001

Exonuclease III-Proofread high-fidelity primer exchange reaction enables ultrasensitive analysis of prostate cancer MicroRNA

Yao, J., Deng, G., Li, X., Xia, X., & Yan, J. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.119288

MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer

Aghdam, A. M., Amiri, A., Salarinia, R., Masoudifar, A., Ghasemi, F., & Mirzaei, H. (2019) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2019025273 · Cited by 82 · see citing works

The Potential Diagnostic and Prognostic Value of Circulating MicroRNAs in the Assessment of Patients With Prostate Cancer: Rational and Progress

Samami, E., Pourali, G., Arabpour, M., Fanipakdel, A., Shahidsales, S., Javadinia, S. A., Hassanian, S. M., Mohammadparast, S., & Avan, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.716831 · Cited by 14 · see citing works

MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer

Ghamlouche, F., Yehya, A., Zeid, Y., Fakhereddine, H., Fawaz, J., Liu, Y., Al‐Sayegh, M., & Abou-Kheir, W. G. (2023) · Translational Oncology · doi:10.1016/j.tranon.2022.101613 · Cited by 56 · see citing works

MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics

Gordanpour, A., Nam, R. K., Sugar, L., & Seth, A. K. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.3 · Cited by 51 · see citing works

Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer.

Srivastava, A., Suy, S., Collins, S. P., & Kumar, D. (2011) · PubMed · Cited by 15 · see citing works